NAICS UNIVERSITY · Free research for insurance agents
Biological Product (except Diagnostic) Manufacturing
NAICS 325414 · United States · 2022 edition
This U.S. industry comprises establishments primarily engaged in manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic).
Start the review with products liability.
For Biological Product (except Diagnostic) Manufacturing, the saved research highlights products liability, product recall / contamination, property and equipment. Confirm how these arise in the actual operation, what controls are used and whether additional services change the proposed coverage.
Questions to ask
- What specific biological products are manufactured — vaccines, toxoids, blood fractions, culture media, or a combination?
- What is the distribution channel and end-use population for the products?
- Is the operation a primary brand owner, contract manufacturer, or both?
- What is the FDA regulatory status of all products in the portfolio?
- Has the operation experienced any product recalls, FDA warning letters, or adverse event reports in recent years?
- What cold-chain and backup power systems are in place for temperature-sensitive inventory?
- For Biological Product (except Diagnostic) Manufacturing, what should the underwriter know about vaccine or injectable biologic manufacturing with broad consumer distribution?
- For Biological Product (except Diagnostic) Manufacturing, what should the underwriter know about prior product liability claims, recall events, or fda warning letters?
Activities described by this code
Other activities to examine
- Manufacturing in-vitro diagnostic substances: 325413 — In-Vitro Diagnostic Substance Manufacturing;
- Manufacturing pharmaceutical preparations (except biological and in-vitro diagnostic substances): 325412 — Pharmaceutical Preparation Manufacturing
Census classification reference
For educational purposes only. AI-generated insurance research and automated logic can contain errors. Independently verify classification and coverage decisions.
Compare another operationInsurance operations research — draft
Establishments in this class manufacture biological products such as vaccines, toxoids, blood fractions, and culture media derived from plant or animal sources. Operations typically involve highly controlled cleanroom environments, stringent FDA regulatory oversight, complex cold-chain handling, and sophisticated quality-control and batch-testing protocols. Products may be distributed to hospitals, clinics, research institutions, or other manufacturers.
Questions to investigate
- What specific biological products are manufactured — vaccines, toxoids, blood fractions, culture media, or a combination?
- What is the distribution channel and end-use population for the products?
- Is the operation a primary brand owner, contract manufacturer, or both?
- What is the FDA regulatory status of all products in the portfolio?
This insurance research was generated in April 2026. It has not received a complete human review. The October 12, 2026 audit checked codes and titles only, not descriptions or coverage assertions.